ISMRM25 - Alzheimer's & Dementia: From Diagnosis to Treatment

ISMRM & ISMRT Annual Meeting & Exhibition • 10-15 May 2025 • Honolulu, Hawai'i

Alzheimer's & Dementia: From Diagnosis to Treatment

Weekend Course

ORGANIZERS: Kevin Chan, Seung Hong Choi, Kenichi Oishi, Nadya Pyatigorskaya, Christin Sander, Wietske van der Zwaag

Sunday, 11 May 2025

313A

07:45 - 11:45

Moderators: Muriel Bruchhage & Leonardo Rivera-Rivera

Skill Level: Basic to Advanced

Session Number: WE-18

No CME/CE Credit

Session Number: WE-18

Overview
This course will cover the basic neurobiology and pathology of Alzheimer's disease and related dementias. It will cover established imaging biomarkers (PET and MRI), their limitations, and advanced analysis in MRI can add value. The course will also cover the latest advances in imaging changes in the glymphatics and meningeal lymphatics in AD. Finally, the power of large datasets in dementia will be demonstrated, and the value of monitoring novel therapeutics with imaging biomarkers will be discussed.

Target Audience
Scientists and clinicians interested in imaging and Alzheimer's disease and dementia.

Educational Objectives
As a result of attending this course, participants should be able to:
• Describe clinical and new developing imaging biomarkers in Alzheimer's disease and dementia;
• Describe disease progression and how MRI can support diagnosis; and
• Describe the power of multimodal biomarkers, advanced analysis and large datasets.

07:45		Basic Neuropathology of AD Phil Lee
08:15		Neuronal Hyperexcitability and Neurophysiological Manifestations in AD View Presentation Video Kamalini Ranasinghe Impact: Our results demonstrate diverse manifestations of synaptic integration deficits in patients with AD, and their distinct associations with tau and Aβ. Targeting differential manifestations hyperexcitability could guide interventions mitigating excitatory-inhibitory imbalance in AD.
08:45		Biomarkers for Diagnosis: PET/MRI in Alzheimer’s Disease View Presentation Video Yuhei Takado Impact: This talk highlights the role of PET and MRI biomarkers in the diagnosis and staging of Alzheimer’s disease, focusing on the updated 2024 criteria and the integration of imaging in the era of disease-modifying therapies.
09:15		Break & Meet the Teachers
09:45		Large Data in Dementia: CLARITi, SCAN, ADNI, ADRC View Presentation Video Arvin Forghanian-Arani Impact: An outline of the history, workflow, quality control, and MRI protocols of three multi-center studies; the Alzheimer’s Disease Neuroimaging Initiative (ADNI), SCAN, and the ADRC Consortium for Clarity in Alzheimer’s Disease and Related Dementias (ADRD) Research Through Imaging (CLARITi).
10:15		Glymphatics & Meningeal Lymphatics in Alzheimer's Disease and MR-based imaging View Presentation Video Sung-Hong Park Impact: CNS lymphatic vessels were long overlooked until their (re)discovery in 2015. Meningeal lymphatics and glymphatics play key roles in CSF drainage. This talk presents glymphatics and meningeal lymphatics in Alzheimer’s and various MRI techniques for imaging them.
10:45		Novel Therapeutics Including ARIA: Screening & Follow-Up View Presentation Video Ana Franceschi Impact: The goal of this presentation is to provide updated guidelines for MR imaging protocols for ARIA detection, discuss workflows, reporting, and communication practices relevant to anti-amyloid immunotherapy, and highlight necessary steps for successful ARIA monitoring.
11:15		Advanced structural MRI Analysis to Extract Early Biomarkers View Presentation Video Keita Watanabe Impact: Advanced MRI analysis of clinically accessible 3DT1-weighted images enables early biomarker detection for Alzheimer’s disease. This session highlights latest techniques, their clinical advantages, and discusses essential steps for practical implementation.